Four Riffs on Rivaroxaban vs. Warfarin
Author: Maureen Shaffer
Ron Winslow on the WSJ Health Blog points out the interesting and slightly different interpretations of the very same clinical study presented yesterday at the late-breaking sessions of the American Heart Association’s Scientific Meeting.
Here are the four PR riffs on Rivaroxaban vs. Warfarin, aka Coumadin, for Afib and Stroke: Duke, JNJ, Bayer and the AHA weigh in.
You can see the slides and hear the presentation by scrolling down to the ROCKET AF section here.
Watch the video, read Ron’s article, and tell us: what do you think?
To keep up with the best in Good Promotional Practices, subscribe to our GPP RSS feed, our Facebook page, our Twitter stream or our LinkedIn group.
This entry was posted in Editor
and tagged AFib
, American Heart Association
, Atrial Fibrillation
, clinical trial
, Food and Drug Administration
, Johnson & Johnson
. Bookmark the permalink